Exchange Traded Concepts LLC Sells 74 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Exchange Traded Concepts LLC lowered its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 4,062 shares of the biotechnology company’s stock after selling 74 shares during the period. Exchange Traded Concepts LLC’s holdings in United Therapeutics were worth $1,433,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the business. USA Financial Formulas bought a new position in shares of United Therapeutics during the third quarter valued at about $33,000. Brooklyn Investment Group purchased a new position in United Therapeutics in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in United Therapeutics in the third quarter valued at approximately $82,000. MassMutual Private Wealth & Trust FSB boosted its stake in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares during the period. Finally, Values First Advisors Inc. bought a new position in shares of United Therapeutics in the third quarter worth approximately $90,000. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In other United Therapeutics news, Director Christopher Causey sold 510 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now directly owns 3,675 shares in the company, valued at approximately $1,384,115.25. This trade represents a 12.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 14,700 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $964,983.42. The trade was a 85.08 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 139,048 shares of company stock worth $52,435,099. 11.90% of the stock is owned by insiders.

United Therapeutics Trading Down 0.3 %

UTHR stock opened at $369.56 on Tuesday. The stock has a market capitalization of $16.50 billion, a PE ratio of 16.23, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. The stock’s 50 day simple moving average is $365.40 and its 200 day simple moving average is $356.35. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.38 EPS. On average, research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Oppenheimer increased their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. TD Cowen boosted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. HC Wainwright upped their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $378.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.